# oligoNgene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oligongene

- Industry: Biotechnology
- Headquarters: Bucheon, South Korea
- Latest round: Seed (Aug 21, 2023)
- Investors on record: 1

## About

Based in Gyeonggi-do, South Korea, and founded in 2023, Oligo & Gene Pharmaceuticals doing business as oligoNgene operates as a operates as a biotechnology company. In August 2023, the firm raised its seed funding led by investor Genaxis. The firm as of August 2023, is led by its founder and representative director, Park Tae-gwan.

The company engages in the development of treatments for hereditary retinal diseases, occurring in the neural retina and retinal pigment epithelial layer, through adeno-associated virus vector gene and cell therapies. Hereditary retinal disease is a rare and incurable condition that causes blindness owing to abnormalities in the retinal cells that convert light into nerve signals. OligoNgene’s is working on the development of a treatment for such diseases by research on human iPS cell-derived retina organoid.

The company plans to utilize its August 2023 funding to hasten the development of therapies by advancing its retinal organoid production technology.

## Funding rounds

- Seed, Aug 21, 2023 — Genaxis

## Investors

- Genaxis (https://capitalatlas.ai/funds/genaxis) — Seed